Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04220203 | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer | approved for marketing | — | — | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 0 | Jun 26, 2025 | clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 |
| May 20, 2025 |
| clinicaltrials |
| NCT03133988 | Margetuximab Expanded Access Program | approved for marketing | — | — | TerSera Therapeutics LLCINDUSTRY | 0 | Feb 14, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT03763604 | Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 14 | Dec 16, 2024 | clinicaltrials |
| NCT04395508 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04320693 | Expanded Access for IMMU-132 | approved for marketing | — | — | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT02792725 | Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 1 | Oct 31, 2017 | clinicaltrials |
| NCT01240421 | An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory | approved for marketing | — | — | Eisai Inc.INDUSTRY | 3 | May 22, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Jun 26, 2025source: clinicaltrials